Welcome to this week’s edition of the Weekender.
Congratulations to our New Jersey life sciences companies that continue to make an important impact on the industry delivering innovative therapies and drugs to the Patients who need…
BioNJ Member Janssen Biotech announced the FDA has approved YONDELIS® for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
BioNJ Member Bristol-Myers Squibb Company announced that the FDA has approved Yervoy 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.
Vaccines that could help contain and even counter some of the world’s deadliest known bio agents must be stockpiled in specific climate-controlled settings or they could be rendered useless. Princeton-based BioNJ Member Soligenix has partnered with the University of Colorado to develop ThermoVax, a method in which the liquid vaccine is dried out to a powder in a vial that can be stored at elevated temperatures. When the vaccine is needed, it can be reconstituted with sterile water and there is no degradation to the vaccine.
Registration is now open for BioNJ’s Inspiring Women in STEM Conference, designed to encourage and support women involved in all aspects of STEM from biotech, pharmaceutical, chemistry, medical device, technology companies, as well as universities, medical and research institutions. Taking place December 4, the full-day program features forward-thinking presentations, informative panel discussions, audience participation and valuable networking activities. Register now.
Click here to read this week’s Weekender.